Liver Cancer

12 protocols meet the specified criteria

OCR13631

Molecular Analysis for Therapy Choice (MATCH)

OCR14527

A Phase 3 Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM-CSF/Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy

OCR15562

A 5-year Longitudinal Observational Study of the Natural History and Management of Patients with Hepatocellular Carcinoma

OCR15732

Phase II Trial of the PARP1 Inhibitor, Niraparib, in BAP1 and other DNA Damage Response (DDR) Pathway Deficient Neoplasms (UF-STO-ETI-001)

OCR16016

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

OCR16937

A Phase 1 Study of NLG802 for Adult Patients with Recurrent Advanced Solid Tumors

OCR17279

Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors

OCR17388

A Phase 1 Study of Pembrolizumab (MK-3475) in Combination with Recombinant Interleukin-12 in Patients with Solid Tumors

OCR17458

Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors

OCR18317

mMotiv8: A smartphone-based incentive intervention to promote smoking cessation

OCR18503

Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)

OCR19317

REFINE: Regorafenib Observational Study in Hepatocellular Carcinoma